Trial Profile
Non Interventional Study Dealing With the Use of Trabectedin (Yondelis)-Pegylated Liposomal Doxorubicin (Caelyx) in Patient With Platinum-sensitive Relapse
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2020
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Trabectedin (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms PROSPECTYON
- 01 Jul 2020 Results (N=99), subgroup analysis assessing efficacy in platinum-sensitive recurrent Ovarian Cancer, published in the Anticancer Research
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results (n=91; as of Jun 2016) presented at the 42nd European Society for Medical Oncology Congress